Skip to main content

Advertisement

Table 4 Type of antipsychotic and thymoregulator prescribed by age in all Pays de la Loire areas (n = 3 658 000) from July 1, 2013 to June 30, 2014

From: Influence of socioeconomic status on antipsychotic prescriptions among youth in France

  Age Total n = 2706
0–4 y n = 44 5–9 y n = 441 10–14 y n = 1140 15–17 y n = 1081
Antipsychotic type and combination n % n % n % n % n %
SGAP single prescription 6 13.6 133 30.2 392 34.4 369 34.1 900 33.3
FGAP single prescription 36 81.8 237 53.7 447 39.2 390 36.1 1110 41.0
FGAP (only usedTourette) - - 5 1.1 3 0.3 3 0.3 11 0.4
Valproate or Valpromide - - 3 0.7 8 0.7 19 1.7 30 1.1
SGAP + FGAP 2 4.5 62 14.1 262 23.0 252 23.3 578 21.5
SGAP+ Valproate or Valpromide - - 1 0.2 8 0.7 8 0.8 17 0.6
FGAP+ Valproate or Valpromide - - - - 2 0.2 8 0.8 10 0.3
Various combination - - - - 18 1.2 32 3.0 50 1.8
FGAP/SGAP ratio 86.3/18.1 68.9/44.5 63.2/58.6 60.3/58.2 65.1/57.1
  1. SGAP second generation antipsychotic, FGAP first generation antipsychotic, Tourette AP used exclusively in Tourette syndrome in France (pimozide)
  2. TGAP/SGAP ratio encompass all FGAP or SGAP, even if it is co-prescription (related to an amount of prescription more then a number of individuals)